BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
Eli Lilly & Co. expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients, Reuters reports. Lilly plans to release results from a trial of its experimental amyloid-targeting drug donanemab before the end of June. More study data on Leqembi, a rival drug from partners Eisai Co. Ltd. and Biogen Inc., is also expected in the coming months.
1. Ford sues BCBS Association alleging price fixing that drove up costs
2. Benefytt Technologies files for bankruptcy after paying fraud settlements
3. More than 60% of retirees would like a do-over on retirement planning: Survey
4. UnitedHealth revises controversial prior authorization plan for colonoscopies
5. Cyber attack on dental insurance plan compromises nearly 9 million individuals
6. Retirees sue city officials over switch to Medicare Advantage plan